ReviewFrontiers in endocrinology2023
Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus.
Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- Nitric oxide as a mechanistic link between metabolic dysfunction and cognitive decline in type 2 diabetes.Biochemical Society transactions · 2026Review
- Renal Dysfunction in Chronic Obstructive Pulmonary Disease Lung-Kidney Interorgan Crosstalk with Cardiac Mediation.International journal of molecular sciences · 2026Review
- miR-4687-5p promotes the progression of diabetic retinopathy by targeting SIRT2 to mediate inflammatory responses.Diabetology & metabolic syndrome · 2026Article
- A Review of Emerging Biomarkers Connecting Diabetes and Ischemic Stroke: Implications for Early Detection and Risk Stratification.Journal of diabetes research · 2026Review
- Engineered Marine Polysaccharide Carriers for Targeted Delivery in Diabetes Management.International journal of nanomedicine · 2026Review
- Endothelial Arginine Metabolism in Angiogenesis: Mechanistic Insights from Tissue Repair to Tumor Progression.Metabolites · 2025Review
- Endothelial Dysfunction as the Common Pathway Linking Obesity, Hypertension and Atherosclerosis.International journal of molecular sciences · 2025Review
- Gene-Embedded Multi-Modal Networks for Population-Scale Multi-Omics Discovery.bioRxiv : the preprint server for biology · 2025Article
- Research progress of non-coding RNA regulating the role of PANoptosis in diabetes mellitus and its complications.Apoptosis : an international journal on programmed cell death · 2025Review
- Metabolomics in Pathogenic Pathways and Targeted Therapies for Diabetic Neuropathy: A Comprehensive Review.Metabolites · 2025Review
- Dimethylarginines in pediatric CKD: clinical utility of ADMA and SDMA as biomarkers.Frontiers in pediatrics · 2025Article
- Regulation of nitric oxide generation and consumption.International journal of biological sciences · 2025Review
- Bupropion decreases plasma levels of asymmetric dimethylarginine and ameliorates renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1 in rats with adenine-induced chronic renal injury.Frontiers in pharmacology · 2025Article
- Asymmetric dimethylarginine mediates oxidative stress and atrial remodeling in HL-1 cells.Frontiers in medicine · 2025Article
- Risk of Alzheimer's disease and genetically predicted levels of 1400 plasma metabolites: a Mendelian randomization study.Scientific reports · 2024Article
- Article
- Article
- High ADMA Is Associated with Worse Health Profile in Heart Failure Patients Hospitalized for Episodes of Acute Decompensation.Medicina (Kaunas, Lithuania) · 2024Article
- Article
- Inverse association of serum albumin levels with diabetic retinopathy in type 2 diabetic patients: a cross-sectional study.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic microangiopathy is a typical and severe problem in diabetics, including diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, and diabetic cardiomyopathy. Patients with type 2 diabetes and diabetic microvascular complications have significantly elevated levels of Asymmetric dimethylarginine (ADMA), which is an endogenous inhibitor of nitric oxide synthase (NOS). ADMA facilitates the occurrence and progression of microvascular complications in type 2 diabetes through its effects on endothelial cell function, oxidative stress damage, inflammation, and fibrosis. This paper reviews the association between ADMA and microvascular complications of diabetes and elucidates the underlying mechanisms by which ADMA contributes to these complications. It provides a new idea and method for the prevention and treatment of microvascular complications in type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.